Silexion Therapeutics Corp (NASDAQ:SLXN) Stock Short Interest Jumps 1,964.4%

Silexion Therapeutics Corp (NASDAQ:SLXN) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 4,925,958 shares, a growth of 1,964.4% from the September 15th total of 238,617 shares. Currently, 89.3% of the company’s stock are short sold. Based on an average daily trading volume, of 40,442,760 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group downgraded shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Silexion Therapeutics presently has a consensus rating of “Hold”.

Silexion Therapeutics Trading Down 8.6%

Shares of NASDAQ SLXN opened at $0.21 on Friday. Silexion Therapeutics has a 1-year low of $0.21 and a 1-year high of $40.70. The company has a 50-day moving average of $0.54 and a two-hundred day moving average of $3.88. The company has a market cap of $1.19 million, a PE ratio of -0.01 and a beta of -0.29.

Silexion Therapeutics (NASDAQ:SLXN) last released its quarterly earnings data on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, beating the consensus estimate of ($21.20) by $16.03. As a group, equities research analysts forecast that Silexion Therapeutics will post -4.70 earnings per share for the current year.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on developing targeted treatments for cancer, with an emphasis on tumors driven by mutations in the KRAS gene. The company’s primary focus is pancreatic cancer, a disease in which KRAS mutations are common and historically difficult to treat.

Silexion is developing RNA-based therapies designed to suppress cancer-promoting KRAS activity. Its pipeline has included siG12D-LODER, a locally administered therapy intended to deliver small interfering RNA against the KRAS G12D mutation, and SIL-204, a next-generation formulation designed to support broader or systemic delivery of KRAS-targeting treatment.

The company originated in Israel and has conducted its research and clinical development activities through Israeli and international collaborations and clinical programs.